ScoreWhy is Xbrane Biopharma AB ?
1
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(HY) At SEK 64.09 MM has Grown at -51.87%
- NET PROFIT(HY) At SEK -24.07 MM has Grown at -739.68%
- RAW MATERIAL COST(Y) Grown by 101.96% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -72.00%, its profits have fallen by -110.8%
3
Below par performance in long term as well as near term
- Along with generating -72.00% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Xbrane Biopharma AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xbrane Biopharma AB
-100.0%
0.34
9421.64%
OMX Stockholm 30
27.26%
1.74
15.47%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
173.61%
EBIT Growth (5y)
13.12%
EBIT to Interest (avg)
-28.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.41
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.45%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.41
EV to EBIT
-3.57
EV to EBITDA
-4.49
EV to Capital Employed
0.40
EV to Sales
2.85
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11.28%
ROE (Latest)
-14.21%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Bearish
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
NET SALES(Q)
Highest at SEK 46.75 MM
PRE-TAX PROFIT(Q)
Highest at SEK -11.28 MM
NET PROFIT(Q)
Highest at SEK -11.28 MM
-20What is not working for the Company
NET SALES(HY)
At SEK 64.09 MM has Grown at -51.87%
NET PROFIT(HY)
At SEK -24.07 MM has Grown at -739.68%
RAW MATERIAL COST(Y)
Grown by 101.96% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.36 times
Here's what is working for Xbrane Biopharma AB
Net Sales
At SEK 46.75 MM has Grown at 144.61%
over average net sales of the previous four periods of SEK 19.11 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (SEK MM)
Net Sales
Highest at SEK 46.75 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Pre-Tax Profit
Highest at SEK -11.28 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (SEK MM)
Pre-Tax Profit
At SEK -11.28 MM has Grown at 40.52%
over average net sales of the previous four periods of SEK -18.97 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (SEK MM)
Net Profit
Highest at SEK -11.28 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
Here's what is not working for Xbrane Biopharma AB
Debtors Turnover Ratio
Lowest at 1.36 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 101.96% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
